Funded Biobanks

Patient samples are a cornerstone of Lyme disease research. They provide critical insights into disease mechanisms, enable the discovery of reliable biomarkers, and support the evaluation of new diagnostics and therapies. A well-curated biorepository, preserving samples from individuals across different stages of the disease, ensures that researchers have access to consistent, high-quality material for large-scale and reproducible studies. 

More than a collection of specimens, a Lyme disease biorepository fosters collaboration, drives innovation, and transforms today’s research questions into tomorrow’s solutions for patients.  

One of the greatest barriers to progress in Lyme and other tick-borne disease research is the scarcity of high-quality patient samples, especially those paired with detailed clinical information across different stages of illness. Without this critical resource, developing and validating improved diagnostics and treatments remains extremely difficult. Recognizing this unmet need, GLA has been at the forefront of building the infrastructure to close this gap. 

Continuing its leadership in addressing the most urgent gaps in Lyme disease research, GLA went on to support the creation of the first dedicated pediatric Lyme disease biobank in 2018 at Boston Children’s Hospital through Pedi Lyme Net, the nation’s only pediatric Lyme disease research network. This resource extends biobanking to children, providing high-quality samples and clinical data that are deepening understanding of pediatric Lyme disease and paving the way for improved approaches to diagnosis and care.